U.S. Court Rules In Favor Of Daiichi Sanyo In Infringement Suit Against Mylan
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo announced Aug. 3 that a federal court in New Jersey ruled in favor of the company in an infringement lawsuit against U.S. generic drug giant Mylan. The court acknowledged Daiichi Sankyo as the valid patent holder in the U.S. for hypertension drug Azor (amlodipine/olmesartan). Daiichi Sankyo filed the suit after Mylan filed for approval for a generic version for the drug. (Click here for more - Japanese language